↓ Skip to main content
What is this page? Embed badge

Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS

Overview of attention for article published in Future Oncology, March 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
15 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
26 Mendeley
Summary X Wikipedia Dimensions citations
So far, Dimensions has found 16 publications that cite this research output.

16

The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.

This page is provided by Altmetric.